Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HERBALIFE LTD.HLF · Entity 4842 | Chief Executive Officer | September 17, 2018 | September 18, 2018 |
| TUPPERWARE BRANDS CORPTUP · Entity 90566 | Director · Executive Vice Chair | February 27, 2023 | March 20, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HERBALIFE LTD.
Report date September 17, 2018 · Filed September 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 676,802 |
Reported balance
After 2018-09-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-09-17 · Exercise / conversion · Acquired 240,000 · Balance 676,802 F1: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F2: On May 14, 2018, the common stock of Herbalife Nutrition Ltd. split 2-for-1, resulting in the reporting person's acquisition of 218,401 additional shares of common stock. |
| Common StockSEC Table I · non-derivative | Direct | 631,804 |
Reported balance
After 2018-09-17 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2018-09-17 · Disposition to issuer · Disposed 44,998 · Balance 631,804 F1: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 529,720 |
Reported balance
After 2018-09-17 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2018-09-17 · Tax withholding · Disposed 102,084 · Balance 529,720 F1: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 635,906 |
Reported balance
After 2018-09-17 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2018-09-17 · Exercise / conversion · Acquired 106,186 · Balance 635,906 F3: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 613,805 |
Reported balance
After 2018-09-17 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2018-09-17 · Disposition to issuer · Disposed 22,101 · Balance 613,805 F3: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 569,786 |
Reported balance
After 2018-09-17 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2018-09-17 · Tax withholding · Disposed 44,019 · Balance 569,786 F3: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 685,804 |
Reported balance
After 2018-09-17 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2018-09-17 · Exercise / conversion · Acquired 116,018 · Balance 685,804 F4: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 629,710 |
Reported balance
After 2018-09-17 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2018-09-17 · Disposition to issuer · Disposed 56,094 · Balance 629,710 F4: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 598,339 |
Reported balance
After 2018-09-17 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2018-09-17 · Tax withholding · Disposed 31,371 · Balance 598,339 F4: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 835,191 |
Reported balance
After 2018-09-17 transaction · row 10
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 10 · 2018-09-17 · Exercise / conversion · Acquired 236,852 · Balance 835,191 F5: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 738,941 |
Reported balance
After 2018-09-17 transaction · row 11
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 11 · 2018-09-17 · Disposition to issuer · Disposed 96,250 · Balance 738,941 F5: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 665,335 |
Reported balance
After 2018-09-17 transaction · row 12
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 12 · 2018-09-17 · Tax withholding · Disposed 73,606 · Balance 665,335 F5: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 774,657 |
Reported balance
After 2018-09-17 transaction · row 13
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 13 · 2018-09-17 · Exercise / conversion · Acquired 109,322 · Balance 774,657 F6: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 695,723 |
Reported balance
After 2018-09-17 transaction · row 14
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 14 · 2018-09-17 · Disposition to issuer · Disposed 78,934 · Balance 695,723 F6: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 679,812 |
Reported balance
After 2018-09-17 transaction · row 15
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 15 · 2018-09-17 · Tax withholding · Disposed 15,911 · Balance 679,812 F6: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 846,616 |
Reported balance
After 2018-09-17 transaction · row 16
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 16 · 2018-09-17 · Exercise / conversion · Acquired 166,804 · Balance 846,616 F7: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 755,842 |
Reported balance
After 2018-09-17 transaction · row 17
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 17 · 2018-09-17 · Disposition to issuer · Disposed 90,774 · Balance 755,842 F7: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 716,038 |
Reported balance
After 2018-09-17 transaction · row 18
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 18 · 2018-09-17 · Tax withholding · Disposed 39,804 · Balance 716,038 F7: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 960,736 |
Reported balance
After 2018-09-17 transaction · row 19
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 19 · 2018-09-17 · Exercise / conversion · Acquired 244,698 · Balance 960,736 F8: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 893,154 |
Reported balance
After 2018-09-17 transaction · row 20
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 20 · 2018-09-17 · Disposition to issuer · Disposed 67,582 · Balance 893,154 F8: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 800,431 |
Reported balance
After 2018-09-17 transaction · row 21
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 21 · 2018-09-17 · Tax withholding · Disposed 92,723 · Balance 800,431 F8: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 966,931 |
Reported balance
After 2018-09-17 transaction · row 22
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 22 · 2018-09-17 · Exercise / conversion · Acquired 166,500 · Balance 966,931 F9: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 894,722 |
Reported balance
After 2018-09-17 transaction · row 23
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 23 · 2018-09-17 · Disposition to issuer · Disposed 72,209 · Balance 894,722 F9: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 845,358 |
Reported balance
After 2018-09-17 transaction · row 24
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 24 · 2018-09-17 · Tax withholding · Disposed 49,364 · Balance 845,358 F9: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 893,890 |
Reported balance
After 2018-09-17 transaction · row 25
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 25 · 2018-09-17 · Exercise / conversion · Acquired 48,532 · Balance 893,890 F10: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 866,364 |
Reported balance
After 2018-09-17 transaction · row 26
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 26 · 2018-09-17 · Disposition to issuer · Disposed 27,526 · Balance 866,364 F10: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 855,366 |
Reported balance
After 2018-09-17 transaction · row 27
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 27 · 2018-09-17 · Tax withholding · Disposed 10,998 · Balance 855,366 F10: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 880,874 |
Reported balance
After 2018-09-17 transaction · row 28
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 28 · 2018-09-17 · Exercise / conversion · Acquired 25,508 · Balance 880,874 F11: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 867,638 |
Reported balance
After 2018-09-17 transaction · row 29
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 29 · 2018-09-17 · Disposition to issuer · Disposed 13,236 · Balance 867,638 F11: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Common StockSEC Table I · non-derivative | Direct | 861,213 |
Reported balance
After 2018-09-17 transaction · row 30
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 30 · 2018-09-17 · Tax withholding · Disposed 6,425 · Balance 861,213 F11: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $10.33 · Expires 2020-01-04 | Direct | 0 |
Reported balance
After 2018-09-17 transaction · row 31
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 31 · 2018-09-17 · Exercise / conversion · Disposed 240,000 · Balance 0 F1: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F12: These SARS were previously reported as covering 120,000 shares at an exercise price of $20.67 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $11.47 · Expires 2020-05-07 | Direct | 0 |
Reported balance
After 2018-09-17 transaction · row 32
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 32 · 2018-09-17 · Exercise / conversion · Disposed 106,186 · Balance 0 F3: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F13: These SARS were previously reported as covering 66,366 shares at an exercise price of $22.94 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $26.65 · Expires 2021-05-18 | Direct | 0 |
Reported balance
After 2018-09-17 transaction · row 33
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 33 · 2018-09-17 · Exercise / conversion · Disposed 116,018 · Balance 0 F4: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F14: These SARS were previously reported as covering 58,009 shares at an exercise price of $53.29 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $22.40 · Expires 2022-05-31 | Direct | 0 |
Reported balance
After 2018-09-17 transaction · row 34
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 34 · 2018-09-17 · Exercise / conversion · Disposed 236,852 · Balance 0 F5: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F15: These SARS were previously reported as covering 118,426 shares at an exercise price of $44.79 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $39.79 · Expires 2023-12-19 | Direct | 0 |
Reported balance
After 2018-09-17 transaction · row 35
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 35 · 2018-09-17 · Exercise / conversion · Disposed 109,322 · Balance 0 F6: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F16: These SARS were previously reported as covering 54,661 shares at an exercise price of $79.58 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $29.99 · Expires 2024-04-30 | Direct | 0 |
Reported balance
After 2018-09-17 transaction · row 36
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 36 · 2018-09-17 · Exercise / conversion · Disposed 166,804 · Balance 0 F7: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F17: These SARS were previously reported as covering 83,402 shares at an exercise price of $59.98 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $15.22 · Expires 2025-03-02 | Direct | 0 |
Reported balance
After 2018-09-17 transaction · row 37
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 37 · 2018-09-17 · Exercise / conversion · Disposed 244,698 · Balance 0 F8: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F18: These SARS were previously reported as covering 122,349 shares at an exercise price of $30.44 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $23.90 · Expires 2025-05-07 | Direct | 0 |
Reported balance
After 2018-09-17 transaction · row 38
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 38 · 2018-09-17 · Exercise / conversion · Disposed 166,500 · Balance 0 F9: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F19: These SARS were previously reported as covering 83,250 shares at an exercise price of $47.80 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2026-05-09 | Direct | 72,798 |
Reported balance
After 2018-09-17 transaction · row 39
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 39 · 2018-09-17 · Exercise / conversion · Disposed 48,532 · Balance 72,798 F10: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F20: On May 9, 2016, the reporting person was granted 60,665 SARs. These SARs vested 20% each on May 9, 2017 and May 9, 2018, and 60% will vest on May 9, 2019. F21: These SARS were previously reported as covering 60,665 shares at an exercise price of $62.51 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $28.60 · Expires 2027-02-27 | Direct | 102,034 |
Reported balance
After 2018-09-17 transaction · row 40
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 40 · 2018-09-17 · Exercise / conversion · Disposed 25,508 · Balance 102,034 F11: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F22: On February 27, 2017, the reporting person was granted 63,771 SARs. These SARs vested 20% on February 27, 2018 and 20% will vest on February 27, 2019 and 60% will vest on February 27, 2020. F23: These SARS were previously reported as covering 63,771 shares at an exercise price of $57.19 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
F2: On May 14, 2018, the common stock of Herbalife Nutrition Ltd. split 2-for-1, resulting in the reporting person's acquisition of 218,401 additional shares of common stock.
F3: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
F4: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
F5: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
F6: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
F7: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
F8: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
F9: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
F10: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
F11: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11.
F12: These SARS were previously reported as covering 120,000 shares at an exercise price of $20.67 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
F13: These SARS were previously reported as covering 66,366 shares at an exercise price of $22.94 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
F14: These SARS were previously reported as covering 58,009 shares at an exercise price of $53.29 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
F15: These SARS were previously reported as covering 118,426 shares at an exercise price of $44.79 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
F16: These SARS were previously reported as covering 54,661 shares at an exercise price of $79.58 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
F17: These SARS were previously reported as covering 83,402 shares at an exercise price of $59.98 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
F18: These SARS were previously reported as covering 122,349 shares at an exercise price of $30.44 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
F19: These SARS were previously reported as covering 83,250 shares at an exercise price of $47.80 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
F20: On May 9, 2016, the reporting person was granted 60,665 SARs. These SARs vested 20% each on May 9, 2017 and May 9, 2018, and 60% will vest on May 9, 2019.
F21: These SARS were previously reported as covering 60,665 shares at an exercise price of $62.51 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
F22: On February 27, 2017, the reporting person was granted 63,771 SARs. These SARs vested 20% on February 27, 2018 and 20% will vest on February 27, 2019 and 60% will vest on February 27, 2020.
F23: These SARS were previously reported as covering 63,771 shares at an exercise price of $57.19 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018.
TUPPERWARE BRANDS CORP
Report date February 27, 2023 · Filed March 20, 2023 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,275 |
Reported balance
After 2023-02-27 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2023-02-27 · Tax withholding · Disposed 1,813 · Balance 52,275 F1: Shares were withheld by the Issuer upon the vesting of the reporting person's February 25, 2022 restricted stock units award to cover the resulting tax liability. On February 25, 2022, the reporting person was granted 6,113 restricted stock units with a vesting schedule of 100% on February 25, 2023, the anniversary of the grant. F2: The Form 4 filed on February 28, 2023 is hereby amended to correct the vesting schedule of the shares granted to the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectGoudis Family Revocable Trust | 424,500 |
Reported balance
Holding disclosure · report date 2023-02-27 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance 424,500 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were withheld by the Issuer upon the vesting of the reporting person's February 25, 2022 restricted stock units award to cover the resulting tax liability. On February 25, 2022, the reporting person was granted 6,113 restricted stock units with a vesting schedule of 100% on February 25, 2023, the anniversary of the grant.
F2: The Form 4 filed on February 28, 2023 is hereby amended to correct the vesting schedule of the shares granted to the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2018 Filed Mar 9, 2018 00:26 UTC | HERBALIFE LTD. HLF · Entity 4842 | Exercise / conversionStock Appreciation Rights · Derivative | 83,333 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001209191-18-018327 · doc4.xml · derivative · entry 4 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,333 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person received 36,948 shares of common stock upon the net exercise of 83,333 stock appreciation rights ("SARS"). The reporting person forfeited 5,792 shares of common stock underlying the SARS in payment of the exercise price and 40,593 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 7, 2018 of $98.13. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 00:26 UTC | HERBALIFE LTD. HLF · Entity 4842 | Tax withholdingCommon Stock | 40,593 | $98.13 | $3,983,391.09 |
DisclosureSEC source: 0001209191-18-018327 · doc4.xml · nonDerivative · entry 3 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,401 F1 · kind: The reporting person received 36,948 shares of common stock upon the net exercise of 83,333 stock appreciation rights ("SARS"). The reporting person forfeited 5,792 shares of common stock underlying the SARS in payment of the exercise price and 40,593 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 7, 2018 of $98.13. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 00:26 UTC | HERBALIFE LTD. HLF · Entity 4842 | Disposition to issuerCommon Stock | 5,792 | $98.13 | $568,368.96 |
DisclosureSEC source: 0001209191-18-018327 · doc4.xml · nonDerivative · entry 2 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,994 F1 · kind: The reporting person received 36,948 shares of common stock upon the net exercise of 83,333 stock appreciation rights ("SARS"). The reporting person forfeited 5,792 shares of common stock underlying the SARS in payment of the exercise price and 40,593 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 7, 2018 of $98.13. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 00:26 UTC | HERBALIFE LTD. HLF · Entity 4842 | Exercise / conversionCommon Stock | 83,333 | $6.82 | $568,331.06 |
DisclosureSEC source: 0001209191-18-018327 · doc4.xml · nonDerivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person received 36,948 shares of common stock upon the net exercise of 83,333 stock appreciation rights ("SARS"). The reporting person forfeited 5,792 shares of common stock underlying the SARS in payment of the exercise price and 40,593 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on March 7, 2018 of $98.13. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 02:15 UTC | HERBALIFE LTD. HLF · Entity 4842 | GrantCommon Stock | 14,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013685 · doc4.xml · nonDerivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,453 F1 · kind: Consists of restricted stock units ("RSU") under the Herbalife Ltd. 2014 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of Herbalife Ltd. common stock on vesting. This award will vest 20% each on February 26, 2019 and February 26, 2020, and 60% on February 26, 2021. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:15 UTC | HERBALIFE LTD. HLF · Entity 4842 | GrantStock Appreciation Rights · Derivative | 12,754 | $0.00 Strike: $57.19 | $0.00 |
DisclosureSEC source: 0001209191-18-013685 · doc4.xml · derivative · entry 5 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,754 Underlying: Common Stock · 12,754 shares Expires 2027-02-27 F5 · kind: On February 27, 2017, the reporting person was granted an award of 63,771 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2017, 2018 and 2019. The performance criteria for 2017 was met, resulting in 12,754 SARs which will vest on February 27, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:15 UTC | HERBALIFE LTD. HLF · Entity 4842 | GrantStock Appreciation Rights · Derivative | 12,133 | $0.00 Strike: $62.51 | $0.00 |
DisclosureSEC source: 0001209191-18-013685 · doc4.xml · derivative · entry 4 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,266 Underlying: Common Stock · 12,133 shares Expires 2026-05-09 F4 · kind: On May 9, 2016, the reporting person was granted an award of 60,665 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 12,133 SARs which will vest on May 9, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:15 UTC | HERBALIFE LTD. HLF · Entity 4842 | GrantStock Appreciation Rights · Derivative | 49,950 | $0.00 Strike: $47.80 | $0.00 |
DisclosureSEC source: 0001209191-18-013685 · doc4.xml · derivative · entry 3 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,250 Underlying: Common Stock · 49,950 shares Expires 2025-05-07 F3 · kind: On May 7, 2015, the reporting person was granted an award of 83,250 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2017 was met, resulting in 49,950 SARs which will vest on May 7, 2018. Read SEC document |
| February 22, 2018 Filed Feb 27, 2018 02:15 UTC | HERBALIFE LTD. HLF · Entity 4842 | GrantStock Appreciation Rights · Derivative | 73,409 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-18-013685 · doc4.xml · derivative · entry 2 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,349 Underlying: Common Stock · 73,409 shares Expires 2025-03-02 F2 · kind: On March 2, 2015, the reporting person was granted an award of 122,349 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2017 was met, resulting in 73,409 SARs which will vest on March 2, 2018. Read SEC document |
| February 23, 2017 Filed Feb 28, 2017 00:18 UTC | HERBALIFE LTD. HLF · Entity 4842 | GrantStock Appreciation Rights · Derivative | 12,133 | $0.00 Strike: $62.51 | $0.00 |
DisclosureSEC source: 0001209191-17-014998 · doc4.xml · derivative · entry 4 GOUDIS RICHARD · CIK 0001311175 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,133 Underlying: Common Stock · 12,133 shares Expires 2026-05-09 F4 · balance_after: On May 9, 2016, the reporting person was granted an award of 60,665 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2016, 2017 and 2018. The performance criteria for 2016 was met, resulting in 12,133 SARs which will vest on May 9, 2017. Read SEC document |
| February 23, 2017 Filed Feb 28, 2017 00:18 UTC | HERBALIFE LTD. HLF · Entity 4842 | GrantStock Appreciation Rights · Derivative | 16,650 | $0.00 Strike: $47.80 | $0.00 |
DisclosureSEC source: 0001209191-17-014998 · doc4.xml · derivative · entry 3 GOUDIS RICHARD · CIK 0001311175 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,300 Underlying: Common Stock · 16,650 shares Expires 2025-05-07 F3 · balance_after: On May 7, 2015, the reporting person was granted an award of 83,250 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2016 was met, resulting in 16,650 SARs which will vest on May 7, 2017. Read SEC document |
| February 23, 2017 Filed Feb 28, 2017 00:18 UTC | HERBALIFE LTD. HLF · Entity 4842 | GrantStock Appreciation Rights · Derivative | 24,470 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-17-014998 · doc4.xml · derivative · entry 2 GOUDIS RICHARD · CIK 0001311175 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,940 Underlying: Common Stock · 24,470 shares Expires 2025-03-02 F2 · balance_after: On March 2, 2015, the reporting person was granted an award of 122,349 SARs. The amount and timing of the vesting of these SARs is dependent upon the achievement by the Company of certain performance criteria for each of fiscal 2015, 2016 and 2017. The performance criteria for 2016 was met, resulting in 24,470 SARs which will vest on March 2, 2017. Read SEC document |
| February 23, 2017 Filed Feb 28, 2017 00:18 UTC | HERBALIFE LTD. HLF · Entity 4842 | GrantStock Appreciation Rights · Derivative | 50,041 | $0.00 Strike: $59.98 | $0.00 |
DisclosureSEC source: 0001209191-17-014998 · doc4.xml · derivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,402 Underlying: Common Stock · 50,041 shares Expires 2024-04-30 F1 · balance_after: On April 30, 2014, the reporting person was granted an award of 83,402 stock appreciation rights ("SARs"). The amount and timing of the vesting of these SARs is dependent upon the achievement by Herbalife Ltd. (the "Company") of certain performance criteria for each of fiscal 2014, 2015 and 2016. The performance criteria for 2016 was met, resulting in 50,041 SARs which will vest on April 30, 2017. Read SEC document |
| April 27, 2016 Filed Dec 30, 2016 21:09 UTC | HERBALIFE LTD. HLF · Entity 4842 | GrantStock Appreciation Rights · Derivative | 32,796 | $0.00 Strike: $79.58 | $0.00 |
DisclosureSEC source: 0001209191-16-157082 · doc4.xml · derivative · entry 1 GOUDIS RICHARD · CIK 0001311175 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,661 Underlying: Common Stock · 32,796 shares Expires 2023-12-19 F1 · derivative.exercise_date: On December 19, 2013, the reporting person was granted an award of 54,661 stock appreciation rights (SARs). The amount and timing of the vesting of these SARs were dependent upon Herbalife Ltd.'s achievement of certain performance criteria for each of fiscal 2013, 2014 and 2015. The performance criteria were met in 2015, resulting in the vesting of 32,796 SARs subject to this award on June 21, 2016. F1 · balance_after: On December 19, 2013, the reporting person was granted an award of 54,661 stock appreciation rights (SARs). The amount and timing of the vesting of these SARs were dependent upon Herbalife Ltd.'s achievement of certain performance criteria for each of fiscal 2013, 2014 and 2015. The performance criteria were met in 2015, resulting in the vesting of 32,796 SARs subject to this award on June 21, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.